search
Back to results

Efficacy Trial of CDB 2914 for Emergency Contraception

Primary Purpose

Emergency Contraception

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CDB-2914
levonorgestrel
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Emergency Contraception focused on measuring emergency contraception, antiprogestin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Menstruating women at least 18 years old; Give voluntary, written informed consent, and agree to observe all study requirements; Request emergency contraception within 72 hours (3 days) after unprotected coitus, as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure; Reports that all acts of unprotected coitus during the current cycle are within 72 hours prior to enrollment; Willing to abstain from further acts of unprotected intercourse during that cycle; History of regular menstrual cycles (mean length of 24-42 days with intra-individual variation of ±5 days); At least one normal menstrual cycle (2 menses) post delivery or abortion; If subject recently discontinued hormonal contraception, one normal menstrual cycle (2 menses) must have been completed before entry in the study For women with a recent history of Depo Provera use, the most recent injection must be at least 3 months before study entry and the subject must have had at least one normal menstrual cycle (2 menses); Available for follow-up for at least the next four weeks. Exclusion Criteria: Currently pregnant (positive high-sensitivity urine pregnancy test); pregnant or breast-feeding within the past two months; use of hormonal methods of contraception during the current or previous two cycles; current user of IUD; tubal ligation; partners with history of vasectomy; unsure about the date of the last menstrual period (+3 days); irregular menstrual cycles as defined in the inclusion criteria; nausea and vomiting within the previous two weeks; impaired hypothalamic-pituitary-adrenal reserve or oral glucocorticoid replacement therapy in the last year. Subjects cannot be currently enrolled in any other investigational trial or re-enrolled in this study.

Sites / Locations

  • California Family Health Council
  • University of Colorado
  • New York University
  • University of Cincinnati
  • University of Pittsburgh
  • Eastern Virginia Medical School

Outcomes

Primary Outcome Measures

Pregnancy (efficacy)

Secondary Outcome Measures

Tolerability (side effects)
Menstrual cycle effects

Full Information

First Posted
December 29, 2005
Last Updated
December 13, 2007
Sponsor
University of Pittsburgh
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT00271583
Brief Title
Efficacy Trial of CDB 2914 for Emergency Contraception
Official Title
A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception
Study Type
Interventional

2. Study Status

Record Verification Date
December 2007
Overall Recruitment Status
Completed
Study Start Date
September 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2001 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Pittsburgh
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objective: To compare the efficacy, safety and tolerance of a 50 mg dose of a new antiprogestin, CDB-2914 with a 0.75 mg bid dose of levonorgestrel as emergency contraception Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception Subjects are randomized to receive a one-time treatment with either one dose of 50 mg CDB-2914 (followed 12 hours later by a placebo) or 2 doses of 0.75 mg of levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed) The primary aim is to evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel.
Detailed Description
Objective: To compare the efficacy, safety and tolerance of a 50 mg dose of a new antiprogestin, CDB-2914 with a 0.75 mg bid dose of levonorgestrel as emergency contraception Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception Duration: A one-time treatment with either CDB-2914 or levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed) Treatment: A one-time treatment with one of the following: Two doses of 0.75 mg of levonorgestrel to be taken 12 hours apart One dose of 50 mg CDB-2914 and a second placebo dose to be taken 12 hours later Study Sites: Multicenter study in the United States Subjects: Women of reproductive age (at least 18 years) at risk of pregnancy within 72 hours of unprotected coitus Sample Size: Approximately 811 women will be enrolled in each treatment group to obtain 1540 evaluable subjects Outcome Evaluations Primary: To evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel. Secondary: To compare the tolerability (as measured by vomiting and nausea) of CDB-2914 used by subjects as an emergency postcoital contraceptive with that of a group of subjects receiving levonorgestrel. Safety/Other: To assess the frequency and intensity of adverse events and the effects on the menstrual cycle of subjects administered CDB-2914 in comparison to subjects given levonorgestrel.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Emergency Contraception
Keywords
emergency contraception, antiprogestin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
1672 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
CDB-2914
Intervention Type
Drug
Intervention Name(s)
levonorgestrel
Primary Outcome Measure Information:
Title
Pregnancy (efficacy)
Time Frame
until follow-up about one week after next menses
Secondary Outcome Measure Information:
Title
Tolerability (side effects)
Time Frame
until follow-up about one week after next menses
Title
Menstrual cycle effects
Time Frame
until follow-up about one week after next menses

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Menstruating women at least 18 years old; Give voluntary, written informed consent, and agree to observe all study requirements; Request emergency contraception within 72 hours (3 days) after unprotected coitus, as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure; Reports that all acts of unprotected coitus during the current cycle are within 72 hours prior to enrollment; Willing to abstain from further acts of unprotected intercourse during that cycle; History of regular menstrual cycles (mean length of 24-42 days with intra-individual variation of ±5 days); At least one normal menstrual cycle (2 menses) post delivery or abortion; If subject recently discontinued hormonal contraception, one normal menstrual cycle (2 menses) must have been completed before entry in the study For women with a recent history of Depo Provera use, the most recent injection must be at least 3 months before study entry and the subject must have had at least one normal menstrual cycle (2 menses); Available for follow-up for at least the next four weeks. Exclusion Criteria: Currently pregnant (positive high-sensitivity urine pregnancy test); pregnant or breast-feeding within the past two months; use of hormonal methods of contraception during the current or previous two cycles; current user of IUD; tubal ligation; partners with history of vasectomy; unsure about the date of the last menstrual period (+3 days); irregular menstrual cycles as defined in the inclusion criteria; nausea and vomiting within the previous two weeks; impaired hypothalamic-pituitary-adrenal reserve or oral glucocorticoid replacement therapy in the last year. Subjects cannot be currently enrolled in any other investigational trial or re-enrolled in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Diana Blithe, PhD
Organizational Affiliation
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Official's Role
Principal Investigator
Facility Information:
Facility Name
California Family Health Council
City
Los Angeles
State/Province
California
Country
United States
Facility Name
University of Colorado
City
Denver
State/Province
Colorado
Country
United States
Facility Name
New York University
City
New York
State/Province
New York
Country
United States
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15215
Country
United States
Facility Name
Eastern Virginia Medical School
City
Norfolk
State/Province
Virginia
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17077229
Citation
Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2006 Nov;108(5):1089-97. doi: 10.1097/01.AOG.0000239440.02284.45.
Results Reference
result

Learn more about this trial

Efficacy Trial of CDB 2914 for Emergency Contraception

We'll reach out to this number within 24 hrs